Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/5/2023 | $15.00 | Overweight | JP Morgan |
| 1/5/2023 | $15.00 | Sector Outperform | Scotiabank |
| 12/21/2022 | $7.50 → $14.00 | Neutral → Overweight | Piper Sandler |
| 8/25/2022 | $8.00 | Underperform | Credit Suisse |
| 6/3/2022 | $7.50 | Neutral | Piper Sandler |
| 2/16/2022 | $40.00 → $32.00 | Buy | BofA Securities |
| 2/16/2022 | $75.00 → $50.00 | Overweight | JP Morgan |
| 2/16/2022 | $54.00 → $21.00 | Neutral | Goldman |
JP Morgan resumed coverage of Adaptive Biotechnologies with a rating of Overweight and set a new price target of $15.00
Scotiabank initiated coverage of Adaptive Biotechnologies with a rating of Sector Outperform and set a new price target of $15.00
Piper Sandler upgraded Adaptive Biotechnologies from Neutral to Overweight and set a new price target of $14.00 from $7.50 previously
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The increased clonoSEQ® Medicare Gapfill rate and the extensio
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostics Services Program (MolDX), has expanded coverage of clonoSEQ® to include detection and monitoring of
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 ho
For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2. “Today’s authorization further und
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit
SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)
SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The increased clonoSEQ® Medicare Gapfill rate and the extensio
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 ho
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. "We had another strong quarter with MRD revenue growth of 36% and delivered significant reductions in operating spend and cash burn versus prior year," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "I am encouraged by our progress towards MRD profitability and our execution on key Immune Medicine prog
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum. The PLTR Trade Ark Invest, through its ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), purchased 199,372 shares of Palantir, a significant addition to its portfolio. The value of this trade, based on the closing price of $25.88 on the same day, stands at approximately $5.16 million. Palantir has recently been praised as an ‘AI Halo’ play by momentum investors. The company was added to BofA Securities’ top 10 best U.S. ideas list for the third quarter, highlighting its growing popularity in the AI sector. Joe Terranova of V
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 17.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $41.873 million which beat the analyst consensus estimate of $38.784 million by 7.96 percent. This is a 11.23 percent increase over sales of $37.647 million the same period last year.